News: Healthcare-focused global capability centres struggle with gender diversity, with only 28% women in the workforce, and ...

The global market for community acquired bacterial pneumonia (CABP) treatment is expected to experience robust growth over ...

Shares of Merck & Co. Inc. MRK inched 0.08% higher to $99.45 Tuesday, on what proved to be an all-around favorable trading ...

A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...

According to the WHO, the proportion of the world’s population aged over 60 years will almost double, from 12% to 22%, ...

Treatment Market. According to a recent market analysis conducted by Future Market Insights, the global molluscum contagiosum ...

Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...

On Friday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.05 which represents a decrease of $-1.47 or -1.48% from the prior close of $99.52. The stock opened at $98.83 and touched a ...

Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that ...

The phase III SOUND trial randomized patients with early breast cancer and a negative axillary ultrasound to SLNB or no ...

In COPD, patients with abnormally high exertional breathlessness on CPET are unlikely to be identified via standard symptom ...

Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...